Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Human papillomavirus vaccines

Shainoor J. Ismail and Shelley L. Deeks
CMAJ September 25, 2017 189 (38) E1212; DOI: https://doi.org/10.1503/cmaj.150465
Shainoor J. Ismail
Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shainoor.ismail@canada.ca shainoor.ismail@gmail.com
Shelley L. Deeks
Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Human papillomavirus (HPV) can lead to cancer

Human papillomavirus is the most common sexually transmitted infection. Persistent infection with a high-risk HPV type causes virtually all cases of cervical cancer and has been associated with 90% of anal, 70% of vaginal, 40% of vulvar and 65% of penile cancers,1 as well as up to 70% of oropharyngeal cancers, which is on the rise.2

HPV vaccines can prevent cancer

Large randomized controlled trials of bivalent (Cervarix), quadrivalent (Gardasil) and nonavalent (Gardasil9) vaccines show that these vaccines prevent about 70% of anogenital cancers. Nonavalent vaccine prevents up to an additional 14% of anogenital cancers caused by the additional five HPV types. Quadrivalent and nonavalent vaccines also prevent 90% of anogenital warts.1

HPV vaccines are safe

Data from clinical trials and safety surveillance show no evidence of increased frequency of systemic or serious adverse events.1,3 After systematic investigations, the World Health Organization’s Global Advisory Committee on Vaccine Safety4 and the Institute of Medicine issued reports concluding that there is no evidence to support an association between HPV vaccine and serious adverse events.5

Canada’s National Advisory Committee on Immunization recommends use of HPV vaccine for females and males

The National Advisory Committee on Immunization has recommended HPV immunization for females aged 9 years and older since 2007 and for males between 9 and 26 years of age since 2012 (see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150465/-/DC1).6 Two doses of HPV vaccine among immunocompetent 9- to 14-year-olds provide similar protective efficacy as three doses in immunocompetent 9- to 26-year-olds.7

HPV vaccination rates are suboptimal

By 2010, all Canadian jurisdictions had implemented school-based immunization programs for girls, and some also have programs for boys. However, only 74.6% of 13- to 14-year-old girls across Canada have received at least one dose of HPV vaccine.8 Physicians can increase vaccine coverage by recommending this vaccine to their patients.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    Updated recommendations on human papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Ottawa: Public Health Agency of Canada; 2016. Available: www.canada.ca/en/public-health/services/publications/healthy-living/9-valent-hpv-vaccine-clarification-minimum-intervals-between-doses-in-hpv-immunization-schedule.html (accessed 2017 Apr. 30).
  2. ↵
    1. Gooi Z,
    2. Chan JY,
    3. Fakhry C
    . The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope 2016;126:894–900.
    OpenUrlPubMed
  3. ↵
    Update on human papillomavirus (HPV) vaccines. Can Commun Dis Rep 2012;38:1–62. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php (accessed 2017 Apr. 30).
    OpenUrl
  4. ↵
    Safety of HPV vaccines: extract from report of GACVS meeting of 2–3 December 2015, published in the WHO Weekly Epidemiological Record of January 22, 2016. Geneva: World Health Organization; 2016. Available: www.who.int/vaccine_safety/committee/topics/hpv/Dec_2015/en/ (accessed 2017 Apr. 30).
  5. ↵
    IOM (Institute of Medicine). Adverse effects of vaccines: evidence and causality. Stratton K, Ford A, Rusch E, et al., editors. Washington: National Academies Press; 2012:505–21. Available: www.nap.edu/catalog/13164/adverse-effects-of-vaccines-evidence-and-causality (accessed 2017 Jan. 30).
  6. ↵
    Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Ottawa: Public Health Agency of Canada; 2017. Available: https://www.canada.ca/en/public-health/services/publications/healthy-living/updated-recommendations-human-papillomavirus-immunization-schedule-immunocompromised-populations.html (accessed 2017 May 30).
  7. ↵
    Update on the recommended human papillomavirus (HPV) vaccine immunization schedule: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Ottawa: Public Health Agency of Canada; 2015. Available: www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html (accessed 2017 Apr. 30).
  8. ↵
    Statistics Canada. Childhood National Immunization Coverage Survey 2015. Available: www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5185 (accessed 2017 Aug. 16).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (38)
CMAJ
Vol. 189, Issue 38
25 Sep 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human papillomavirus vaccines
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human papillomavirus vaccines
Shainoor J. Ismail, Shelley L. Deeks
CMAJ Sep 2017, 189 (38) E1212; DOI: 10.1503/cmaj.150465

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Human papillomavirus vaccines
Shainoor J. Ismail, Shelley L. Deeks
CMAJ Sep 2017, 189 (38) E1212; DOI: 10.1503/cmaj.150465
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Human papillomavirus (HPV) can lead to cancer
    • HPV vaccines can prevent cancer
    • HPV vaccines are safe
    • Canada’s National Advisory Committee on Immunization recommends use of HPV vaccine for females and males
    • HPV vaccination rates are suboptimal
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bedbugs
  • Epinephrine in anaphylaxis
  • Achalasia with megaesophagus
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire